Most discovery teams can list a hundred plausible targets. Deciding which few deserve lab time and budget is the hard part.
That’s the question behind Target Intelligence, a new offering from BioSymetrics. This offering is being shaped by domain experts with backgrounds in biology and drug discovery, bringing scientific context to every target assessment.
For each candidate, we bring together human genetics, disease and model-system evidence, and predictions from our Phenograph™, then compare targets side by side. The result is a short list with the evidence for and against each target, including where the gaps are.
The difference is what happens next. Nominated targets can move straight into our CRISPR zebrafish models, with automated computer-vision phenotyping and compound screening, so a ranked list becomes experimental data without changing vendors.
We’ll be giving partners a first look next week at BIO-Europe, with a broader launch and webinar in the coming weeks. Stay tuned and follow us for more updates on our Target Intelligence platform!
#DrugDiscovery #TargetDiscovery #AI #Biotech #PrecisionMedicine
That’s the question behind Target Intelligence, a new offering from BioSymetrics. This offering is being shaped by domain experts with backgrounds in biology and drug discovery, bringing scientific context to every target assessment.
For each candidate, we bring together human genetics, disease and model-system evidence, and predictions from our Phenograph™, then compare targets side by side. The result is a short list with the evidence for and against each target, including where the gaps are.
The difference is what happens next. Nominated targets can move straight into our CRISPR zebrafish models, with automated computer-vision phenotyping and compound screening, so a ranked list becomes experimental data without changing vendors.
We’ll be giving partners a first look next week at BIO-Europe, with a broader launch and webinar in the coming weeks. Stay tuned and follow us for more updates on our Target Intelligence platform!
#DrugDiscovery #TargetDiscovery #AI #Biotech #PrecisionMedicine
